We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ampio Pharmaceuticals announces positive results from Optina trial

Ampio Pharmaceuticals announces positive results from Optina trial

October 8, 2013
CenterWatch Staff

Ampio Pharmaceuticals, a development stage biopharmaceutical company, has announced interim results from the ongoing 450 patient, dose finding, 505(b)(2) study of Optina as a treatment for Diabetic Macular Edema (DME). This interim analysis was conducted by an Independent Data Review Committee (IDRC) comprised of a statistician and an ophthalmologist/retinologist, who were permitted to view the unmasked data from the trial. At least 30% of patients had reached the first four-week time point and their clinical results were considered representative data for the trial.

Dr. Vaughan Clift, Ampio's chief regulatory officer, said, "As is common with interim analyses of this sort, the analysis parameters were defined a priori and could have resulted in three possible scenarios, including termination of the study due to lack of efficacy or safety concerns, delayed analysis if no conclusion could be drawn or indication of an optimum dose if sufficient differentiation from placebo was present to indicate clinical benefit and no serious adverse events. The IDRC elected the third option.

IDRC said, "After a thorough review of the interim data from the ongoing study, it was determined that there was a treatment dosage that was demonstrating a potentially beneficial anatomic effect.  Given that there were no significant safety concerns identified in the study to date, a recommendation to continue the trial was made."

Clift said, "This IDRC decision will allow for the continuation and completion of the trial and, importantly, the immediate initiation of an open label extension study using this optimum dose of Optina for all patients who have completed the trial and wish to continue treatment for an additional 12 weeks. Patients who received either dose of Optina in the masked trial and those who received placebo will be eligible for inclusion in this open label extension of the trial.”

Patient enrollment now exceeds 250 patients. The trial is expected to be completed in the first quarter of 2014. FDA has agreed to the 505(b)(2) pathway for this drug which, given no significant safety concerns, could allow approval based on this single clinical trial.

Global News Clinical Intelligence

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing